Press Releases News Year None202020192018201720162015201420132012 IVERIC bio Appoints Abraham Scaria, PhD, as Chief Scientific Officer Oct 29, 2019 | IVERIC bio’s Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Oct 28, 2019 | CORRECTING and REPLACING IVERIC bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference Sep 30, 2019 | IVERIC bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference Sep 30, 2019 | IVERIC bio to Present at the Ladenburg Thalmann 2019 Healthcare Conference Sep 17, 2019 | IVERIC bio to Host Inaugural Gene Therapy R&D Investor Day on September 13, 2019 Sep 04, 2019 | IVERIC bio to Present at the Wedbush PacGrow Healthcare Conference Aug 07, 2019 | IVERIC bio Reports Second Quarter 2019 Financial and Operating Results Aug 01, 2019 | IVERIC bio to Report Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019 Jul 25, 2019 | IVERIC bio Announces Successful Advancement of LCA10 Minigene Program and Expansion of Orphan Gene Therapy Portfolio with USH2A-Related Inherited Retinal Diseases Program Jul 23, 2019 | Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
IVERIC bio’s Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Oct 28, 2019 |
CORRECTING and REPLACING IVERIC bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference Sep 30, 2019 |
IVERIC bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference Sep 30, 2019 |
IVERIC bio to Report Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019 Jul 25, 2019 |
IVERIC bio Announces Successful Advancement of LCA10 Minigene Program and Expansion of Orphan Gene Therapy Portfolio with USH2A-Related Inherited Retinal Diseases Program Jul 23, 2019 |
Press Releases News Year None202020192018201720162015201420132012 IVERIC bio Appoints Abraham Scaria, PhD, as Chief Scientific Officer Oct 29, 2019 | IVERIC bio’s Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Oct 28, 2019 | CORRECTING and REPLACING IVERIC bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference Sep 30, 2019 | IVERIC bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference Sep 30, 2019 | IVERIC bio to Present at the Ladenburg Thalmann 2019 Healthcare Conference Sep 17, 2019 | IVERIC bio to Host Inaugural Gene Therapy R&D Investor Day on September 13, 2019 Sep 04, 2019 | IVERIC bio to Present at the Wedbush PacGrow Healthcare Conference Aug 07, 2019 | IVERIC bio Reports Second Quarter 2019 Financial and Operating Results Aug 01, 2019 | IVERIC bio to Report Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019 Jul 25, 2019 | IVERIC bio Announces Successful Advancement of LCA10 Minigene Program and Expansion of Orphan Gene Therapy Portfolio with USH2A-Related Inherited Retinal Diseases Program Jul 23, 2019 | Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
IVERIC bio’s Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Oct 28, 2019 |
CORRECTING and REPLACING IVERIC bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference Sep 30, 2019 |
IVERIC bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference Sep 30, 2019 |
IVERIC bio to Report Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019 Jul 25, 2019 |
IVERIC bio Announces Successful Advancement of LCA10 Minigene Program and Expansion of Orphan Gene Therapy Portfolio with USH2A-Related Inherited Retinal Diseases Program Jul 23, 2019 |
